Defibrotide: Properties and clinical use of an old/new drug

Vascular Pharmacology

Volumn 59, Issue 1-2, 2013, Pages 1-10

  Pescador, R ^a   Capuzzi, L ^a   Mantovani, M ^a   Fulgenzi, A ^a   Ferrero, M E ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE   (Italy)

Author keywords

Defibrotide; Endothelial activation; Inflammation; Venous occlusive disease

Indexed keywords

CYCLIC AMP; DEFIBROTIDE; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 8; LEUKOTRIENE B4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELPHALAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PEPTIDOLEUKOTRIENE; PLATELET DERIVED GROWTH FACTOR BB; PREDNISONE; PROSTACYCLIN; PROSTAGLANDIN E2; THALIDOMIDE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE ACTIVATING FACTOR; THROMBOMODULIN; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD CLOT LYSIS; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CANCER SURVIVAL; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MEDIATOR RELEASE; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOPHLEBITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; TUMOR VASCULARIZATION; VEIN OCCLUSION;

DEFIBROTIDE; ENDOTHELIAL ACTIVATION; INFLAMMATION; VENOUS OCCLUSIVE DISEASE;

ANIMALS; ENDOTHELIUM; FIBRINOLYTIC AGENTS; HUMANS; POLYDEOXYRIBONUCLEOTIDES;

EID: 84880700119     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2013.05.001     Document Type: Review

References (166)

1. Adams M.R., Jessup W., Hailstones D., Celermajer D.S. l-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation 1997, 95:662-668.
2. Aoki N., Siegfried M., Tsao P., Lento P., Lefer A.M. Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock. Res. Commun. Chem. Pathol. Pharmacol. 1988, 60:275-289.
3. Bach F.H., Robson S.C., Winkler H., Ferran C., Stuhlmeier K.M., Wrighton C.J., Hancock W.W. Barriers to xenotransplantation. Nat. Med. 1995, 1:869-873.
4. Bajaj M.S., Birktoft J.J., Steer S.A., Bajaj S.P. Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost. 2001, 86:959-972.
5. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336:1066-1071.
6. Barroso-Aranda J., Zweifach B.W., Mathison J.C., Schmid-Schonbein G.W. Neutrophil activation, tumor necrosis factor, and survival after endotoxic and hemorrhagic shock. J. Cardiovasc. Pharmacol. 1995, 25(Suppl. 2):S23-S29.
7. Berti F., Rossoni G., Niada R., Folco G., Omini C., Tondo C. Defibrotide, an antithrombotic substance that preserves postsynaptic alpha- and beta-adrenergic function in post acute infarcted rabbit hearts. J. Cardiovasc. Pharmacol. 1986, 8:235-240.
8. Berti F., Rossini G., Omini C., Daffonchio L., Tondo C., Cali G. Defibrotide protects rabbit myocardium from ischemia: relationship with the eicosanoid system. Pol. J. Pharmacol. Pharm. 1987, 39:657-665.
9. Berti F., Rossoni G., Omini C., Folco G., Daffonchio L., Vigano T., Tondo C. Defibrotide, an antithrombotic substance which prevents myocardial contracture in ischemic rabbit heart. Eur. J. Pharmacol. 1987, 135:375-382.
10. Berti F., Rossoni G., Magni F., Caruso D., Omini C., Puglisi L., Galli G. Nonsteroidal antiinflammatory drugs aggravate acute myocardial ischemia in the perfused rabbit heart: a role for prostacyclin. J. Cardiovasc. Pharmacol. 1988, 12:438-444.
11. Berti F., Magni F., Rossoni G., De Angelis L., Galli G. Production and biologic interactions of prostacyclin and platelet-activating factor in acute myocardial ischemia in the perfused rabbit heart. J. Cardiovasc. Pharmacol. 1990, 16:727-732.
12. Berti F., Rossoni G., Biasi G., Buschi A., Mandelli V., Tondo C. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins 1990, 40:337-350.
13. Berti F., Rossoni G., Bianchi G., Alberico P., Tettamanti R., Calvani A.B., Mantovani M., Prino G. Effects of defibrotide on prostacyclin release from isolated rabbit kidneys and protection from post-ischemic acute renal failure in vivo. Eicosanoids 1991, 4:209-215.
14. Berti F., Rossoni G., Galli G., Magni F., Mantovani M., Calvani A.B., Porta R., Prino G. Defibrotide has antiischemic activity in perfused rabbit hearts, preventing tissue Ca++ overloading. Thromb. Res. 1992, 65:13-26.
15. Berti F., Rossoni G., Della Bella D., Villa L.M., Buschi A., Trento F., Berti M., Tondo C. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J. Cardiovasc. Pharmacol. 1993, 22:321-326.
16. Bianchi G., Barone D., Lanzarotti E., Tettamanti R., Porta R., Moltrasio D., Cedro A., Salvetti L., Mantovani M., Prino G. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur. J. Pharmacol. 1993, 238:327-334.
17. Bitterman H., Lefer D.J., Lefer A.M. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock. Naunyn Schmiedeberg's Arch. Pharmacol. 1988, 337:679-686.
18. Blann A.D., Noteboom W.M., Rosendaal F.R. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect?. Br. J. Haematol. 2000, 108:191-193.
19. Bonomini V., Frasca G.M., Raimondi C., Liviano D'arcangelo G., Vangelista A. Effect of a new antithrombotic agent (defibrotide) in acute renal failure due to thrombotic microangiopathy. Nephron 1985, 40:195-200.
20. Bracht F., Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem. Biophys. Res. Commun. 1994, 200:933-937.
21. Bulley S.R., Strahm B., Doyle J., Dupuis L.L. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr. Blood Cancer 2007, 48:700-704.
22. Busse R., Fleming I. Endothelial dysfunction in atherosclerosis. J. Vasc. Res. 1996, 33:181-194.
23. Butenas S., Orfeo T., Mann K.G. Tissue factor in coagulation: which? Where? When?. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1989-1996.
24. Carluccio M.A., Massaro M., Bonfrate C., Siculella L., Maffia M., Nicolardi G., Distante A., Storelli C., De Caterina R. Oleic acid inhibits endothelial activation: a direct vascular antiatherogenic mechanism of a nutritional component in the mediterranean diet. Arterioscler. Thromb. Vasc. Biol. 1999, 19:220-228.
25. Celermajer D.S. Endothelial dysfunction: does it matter? Is it reversible?. J. Am. Coll. Cardiol. 1997, 30:325-333.
26. Cella G., Sbarai A., Mazzaro G., Motta G., Carraro P., Andreozzi G.M., Hoppensteadt D.A., Fareed J. Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clin. Appl. Thromb. Hemost. 2001, 7:225-228.
27. Celotti F., Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. 2001, 43:429-436.
28. Cesaro S., Spiller M., Sartori M.T., Alaggio R., Peruzzo M., Saggiorato G., Bisogno G. Veno-occlusive disease in pediatric patients affected by Wilms tumor. Pediatr. Blood Cancer 2011, 57:258-261.
29. Chiba Y., Ogita T., Ando K., Fujita T. PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. Biochem. Biophys. Res. Commun. 2001, 286:541-546.
30. Chopra R., Eaton J.D., Grassi A., Potter M., Shaw B., Salat C., Neumeister P., Finazzi G., Iacobelli M., Bowyer K., Prentice H.G., Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br. J. Haematol. 2000, 111:1122-1129.
31. Cicala C., Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci. 1998, 62:1817-1824.
32. Cirillo F., Margaglione M., Vecchione G., Ames P.R., Coppola A., Grandone E., Cerbone A.M., Marelli C., Di Minno G. In vitro inhibition by defibrotide of monocyte superoxide anion generation: a possible mechanism for the antithrombotic effect of a polydeoxyribonucleotide-derived drug. Haemostasis 1991, 21:98-105.
33. Coccheri S., Biagi G. Defibrotide. Cardiovasc. Drug Rev. 1991, 9:24.
34. Coccheri S., Nazzari M. Defibrotide as a possible anti-ischemic drug. Semin. Thromb. Hemost. 1996, 22(Suppl. 1):9-14.
35. Coccheri S., Andreozzi G.M., D'Addato M., Gensini G.F. Effects of defibrotide in patients with chronic deep insufficiency. The PROVEDIS study. Int. Angiol. 2004, 23:100-107.
36. Cook, J.A., Halushka, P.V., 1989. Arachidonic acid metabolism in septic shock, New Horizons ed. Society of Critical Care Medicine, Fullerton.
37. Corbacioglu S., Cesaro S., Faraci M., Valteau-Couanet D., Gruhn B., Rovelli A., Boelens J.J., Hewitt A., Schrum J., Schulz A.S., Muller I., Stein J., Wynn R., Greil J., Sykora K.W., Matthes-Martin S., Fuhrer M., O'Meara A., Toporski J., Sedlacek P., Schlegel P.G., Ehlert K., Fasth A., Winiarski J., Arvidson J., Mauz-Korholz C., Ozsahin H., Schrauder A., Bader P., Massaro J., D'Agostino R., Hoyle M., Iacobelli M., Debatin K.M., Peters C., Dini G. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012, 379:1301-1309.
38. Corsi M., Marni A., Gaja G., Ferrero M.E. Prolonged survival of grafted rat hearts by use of defibrotide and cyclosporine. Transplant. Proc. 1993, 25:3281-3282.
39. Corti P., Uderzo C., Tagliabue A., Della Volpe A., Annaloro C., Tagliaferri E., Balduzzi A. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002, 29:542-543.
40. Damtew B., Spagnuolo P.J. Leukotriene C4 from vascular endothelium enhances neutrophil adhesiveness. Prostaglandins Leukot. Essent. Fatty Acids 1997, 56:111-116.
41. DeLeve L.D., Shulman H.M., McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis. 2002, 22:27-42.
42. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996, 384:39-43.
43. Downing L.J., Wakefield T.W., Strieter R.M., Prince M.R., Londy F.J., Fowlkes J.B., Hulin M.S., Kadell A.M., Wilke C.A., Brown S.L., Wrobleski S.K., Burdick M.D., Anderson D.C., Greenfield L.J. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J. Vasc. Surg. 1997, 25:816-827. (discussion 828).
44. Echart C.L., Somaini S., Distaso M., Palumbo A., Richardson P.G., Fareed J., Iacobelli M. Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells. Clin. Appl. Thromb. Hemost. 2012, 18:79-86.
45. Eissner G., Multhoff G., Gerbitz A., Kirchner S., Bauer S., Haffner S., Sondermann D., Andreesen R., Holler E. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002, 100:334-340.
46. Espinosa G., Berman H., Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun. Rev. 2011, 10:664-668.
47. Evangelista V., Piccardoni P., de Gaetano G., Cerletti C. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. Thromb. Haemost. 1992, 67:660-664.
48. Evangelista V., Piccardoni P., Maugeri N., De Gaetano G., Cerletti C. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur. J. Pharmacol. 1992, 216:401-405.
49. Evans T.W., Smithies M. ABC of intensive care: organ dysfunction. BMJ 1999, 318:1606-1609.
50. Falanga A., Vignoli A., Marchetti M., Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003, 17:1636-1642.
51. Ferraresso M., Rigotti P., Stepkowski S.M., Chou T.C., Kahan B.D. Immunosuppressive effects of defibrotide. Transplantation 1993, 56:928-933.
52. Ferrero M.E., Marni A., Gaja G. Prevention of impaired liver metabolism due to ischemia in rats. Efficacy of defibrotide administration. J. Hepatol. 1990, 10:223-227.
53. Ferrero M.E., Corsi M., Marni A., Gaja G. Efficacy of defibrotide treatment in favoring the function of the grafted heart and kidney in rats. Transplant. Proc. 1994, 26:251-252.
54. Ferrero E., Zocchi M.R., Magni E., Panzeri M.C., Curnis F., Rugarli C., Ferrero M.E., Corti A. Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am. J. Physiol. Cell Physiol. 2001, 281:C1173-C1179.
55. Fisher J., Johnston A.M., Holland T.K., McCallum J., Pescador R., Mantovani M., Prino G. Pharmacokinetics, absorption, distribution and disposition of [125I]-defibrotide following intravenous or oral administration in the rat. Thromb. Res. 1993, 70:77-90.
56. Fisher J., Holland T.K., Pescador R., Porta R., Ferro L. Study on pharmacokinetics of radioactive labelled defibrotide after oral or intravenous administration in rats. Thromb. Res. 1996, 81:55-63.
57. Fontana L., Partridge L., Longo V.D. Extending healthy life span - from yeast to humans. Science 2010, 328:321-326.
58. Fortin C.F., McDonald P.P., Fulop T., Lesur O. Sepsis, leukocytes, and nitric oxide (NO): an intricate affair. Shock 2010, 33:344-352.
59. Francischetti I.M., Oliveira C.J., Ostera G.R., Yager S.B., Debierre-Grockiego F., Carregaro V., Jaramillo-Gutierrez G., Hume J.C., Jiang L., Moretz S.E., Lin C.K., Ribeiro J.M., Long C.A., Vickers B.K., Schwarz R.T., Seydel K.B., Iacobelli M., Ackerman H.C., Srinivasan P., Gomes R.B., Wang X., Monteiro R.Q., Kotsyfakis M., Sa-Nunes A., Waisberg M. Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler. Thromb. Vasc. Biol. 2012, 32:786-798.
60. Freiman P.C., Mitchell G.G., Heistad D.D., Armstrong M.L., Harrison D.G. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ. Res. 1986, 58:783-789.
61. Fumagalli G., Angelaccio E., Lombardo N., Clementi F. Morphometric and ultrastructural study of experimental venous thrombosis. Effects of defibrotide, an antithrombotic agent. Haemostasis 1987, 17:361-370.
62. Fumagalli G., Sala C., Angelaccio E., Lombardo N., Clementi F. Thrombolytic activity of defibrotide: a morphometric evaluation in experimental venous thrombosis. Pharmacol. Res. 1989, 21:293-298.
63. Gatto B., Vianini E., Lucatello L., Sissi C., Moltrasio D., Pescador R., Porta R., Palumbo M. Effective DNA inhibitors of cathepsin g by in vitro selection. Int. J. Mol. Sci. 2008, 9:1008-1023.
64. Giedrojc J., Breddin H.K. Anticoagulant and antithrombotic effects of combinations of defibrotide with heparins and other antithrombotic agents in an animal thrombosis model. Thromb. Res. 1991, 63:99-110.
65. Goldsack N.R., Chambers R.C., Dabbagh K., Laurent G.J. Thrombin. Int. J. Biochem. Cell Biol. 1998, 30:641-646.
66. Griffin J.H. Blood coagulation. The thrombin paradox. Nature 1995, 378:337-338.
67. Grodzinska L., Konig E., Schror K. Defibrotide is equipotent to urokinase in stimulating arterial and venous thrombolysis. Pharmacol. Res. Commun. 1987, 19:609-615.
68. Gryglewski R.J., Marcinkiewicz E., Radomski M., Swies J. Prostacyclin and the mechanism of action of defibrotide. Eicosanoids 1989, 2:163-167.
69. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
70. Guglielmelli T., Bringhen S., Palumbo A. Update on the use of defibrotide. Expert Opin. Biol. Ther. 2012, 12:353-361.
71. Hacker H. Signal Transduction Pathways by CpG-DNA 2000, Springer, Berlin.
72. Hathaway C.A., Heistad D.D., Piegors D.J., Miller F.J. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ. Res. 2002, 90:277-283.
73. Haussmann U., Fischer J., Eber S., Scherer F., Seger R., Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006, 91:795-800.
74. Henke P.K., DeBrunye L.A., Strieter R.M., Bromberg J.S., Prince M., Kadell A.M., Sarkar M., Londy F., Wakefield T.W. Viral IL-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis. J. Immunol. 2000, 164:2131-2141.
75. Hohlfeld T., Strobach H., Schror K. Stimulation of prostacyclin synthesis by defibrotide: improved contractile recovery from myocardial "stunning". J. Cardiovasc. Pharmacol. 1991, 17:108-115.
76. Hohlfeld T., Bucha E., Nowak G., Bruggener E., Strobach H., Schror K. Favourable effect of defibrotide in lipid A-induced shock in pigs. Circ. Shock. 1992, 38:122-129.
77. Hohlfeld T., Strobach H., Schror K. Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury. J. Pharmacol. Exp. Ther. 1993, 264:397-405.
78. Hunt B.J., Jurd K.M. Endothelial cell activation. A central pathophysiological process. BMJ 1998, 316:1328-1329.
79. Kleinschmidt S., Wanner G.A., Bussmann D., Kremer J.P., Ziegenfuss T., Menger M.D., Bauer M. Proinflammatory cytokine gene expression in whole blood from patients undergoing coronary artery bypass surgery and its modulation by pentoxifylline. Shock 1998, 9:12-20.
80. Klocking H.P. Acute t-PA release by defibrotide. Thromb. Res. 1992, 66:779-785.
81. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. Prognosis in acute organ-system failure. Ann. Surg. 1985, 202:685-693.
82. Koehl G.E., Geissler E.K., Iacobelli M., Frei C., Burger V., Haffner S., Holler E., Andreesen R., Schlitt H.J., Eissner G. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol. Ther. 2007, 6:686-690.
83. Kourtzelis I., Markiewski M.M., Doumas M., Rafail S., Kambas K., Mitroulis I., Panagoutsos S., Passadakis P., Vargemezis V., Magotti P., Qu H., Mollnes T.E., Ritis K., Lambris J.D. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010, 116:631-639.
84. Krieg A.M., Wu T., Weeratna R., Efler S.M., Love-Homan L., Yang L., Yi A.K., Short D., Davis H.L. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12631-12636.
85. Kubes P., Ward P.A. Leukocyte recruitment and the acute inflammatory response. Brain Pathol. 2000, 10:127-135.
86. Kupatt C., Habazettl H., Goedecke A., Wolf D.A., Zahler S., Boekstegers P., Kelly R.A., Becker B.F. Tumor necrosis factor-alpha contributes to ischemia- and reperfusion-induced endothelial activation in isolated hearts. Circ. Res. 1999, 84:392-400.
87. Kupatt C., Habazettl H., Becker B.F., Boekstegers P. Endothelial activation - a strategic event during postischemic myocardial inflammation. Z Kardiol 2000, 89(Suppl. 9):96-100.
88. Lefer A.M., Aoki N., Mulloy D. Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion. Naunyn Schmiedebergs Arch. Pharmacol. 1990, 341:246-250.
89. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. 2001, 49:281-287.
90. Lobel P., Schror K. Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn Schmiedebergs Arch. Pharmacol. 1985, 331:125-130.
91. Lobel P., Schror K. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits. Atherosclerosis 1989, 80:69-79.
92. Ma X.L., Porta R., Pescador R., Lefer A.M. Novel beneficial mechanisms of defibrotide, a prostacyclin enhancing agent in splanchnic artery occlusion and reperfusion in rats. Methods Find. Exp. Clin. Pharmacol. 1991, 13:667-674.
93. Makarov S.S. NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol. Med. Today 2000, 6:441-448.
94. Masini E., Lupini M., Mugnai L., Raspanti S., Mannaioni P.F. Polydeoxyribonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion. Br. J. Pharmacol. 1995, 115:629-635.
95. McEver R.P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb. Haemost. 2001, 86:746-756.
96. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365:2205-2219.
97. Mitsiades C.S., Rouleau C., Echart C., Menon K., Teicher B., Distaso M., Palumbo A., Boccadoro M., Anderson K.C., Iacobelli M., Richardson P.G. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin. Cancer Res. 2009, 15:1210-1221.
98. Murakami K., Okajima K., Uchiba M., Johno M., Nakagaki T., Okabe H., Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996, 87:642-647.
99. Murrin R.J., Murray J.A. Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev. 2006, 20:51-60.
100. Mussoni L., Raczka E., Chmielewska J., Donati M.B., Latallo Z.S. Plasminogen assay in rabbit, rat and mouse plasma using the chromogenic substrate s-2251. Thromb. Res. 1979, 15:341-349.
101. Niada R., Mantovani M., Prino G., Pescador R., Berti F., Omini C., Folco G.C. Antithrombotic activity of a polydeoxyribonucleotidic substance extracted from mammalian organs: a possible link with prostacyclin. Thromb. Res. 1981, 23:233-246.
102. Niada R., Mantovani M., Prino G., Pescador R., Porta R., Berti F., Folco G.C., Omini C., Vigano T. PGI2-generation and antithrombotic activity of orally administered defibrotide. Pharmacol. Res. Commun. 1982, 14:949-957.
103. Niada R., Porta R., Pescador R., Mantovani M., Prino G. Cardioprotective effects of defibrotide in acute myocardial ischemia in the cat. Thromb. Res. 1985, 38:71-81.
104. Niada R., Porta R., Pescador R., Mantovani M., Prino G. Protective activity of defibrotide against lethal acute myocardial ischemia in the cat. Thromb. Res. 1986, 42:363-374.
105. Palmer K.J., Goa K.L. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993, 45:259-294.
106. Palomo M., Diaz-Ricart M., Rovira M., Escolar G., Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2011, 17:497-506.
107. Palumbo A., Larocca A., Genuardi M., Kotwica K., Gay F., Rossi D., Benevolo G., Magarotto V., Cavallo F., Bringhen S., Rus C., Masini L., Iacobelli M., Gaidano G., Mitsiades C., Anderson K., Boccadoro M., Richardson P. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica 2010, 95:1144-1149.
108. Parrillo J.E. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 1993, 328:1471-1477.
109. Pasceri V., Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999, 100:2124-2126.
110. Paul W., Gresele P., Momi S., Bianchi G., Page C.P. The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. Br. J. Pharmacol. 1993, 110:1565-1571.
111. Pellegatta F., Lu Y., Radaelli A., Zocchi M.R., Ferrero E., Chierchia S., Gaja G., Ferrero M.E. Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br. J. Pharmacol. 1996, 118:471-476.
112. Penn M.S., Topol E.J. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ. Res. 2001, 89:1-2.
113. Periti P. Current treatment of sepsis and endotoxaemia. Expert Opin. Pharmacother. 2000, 1:1203-1217.
114. Pescador R., Mantovani M., Prino G., Madonna M. Pharmacokinetics of defibrotide and of its profibrinolytic activity in the rabbit. Thromb. Res. 1983, 30:1-11.
115. Pescador R., Porta R., Conz A., Mantovani M., Prino G. Defibrotide decreases cholesterol amount in hypercholesterolemic rabbit aorta, with no modification of plasma or lipoprotein cholesterol. Life Sci. 1989, 44:789-797.
116. Pescador R., Tettamanti R., Salvetti L., Conto A., Barone D., Porta R., Mantovani M., Ferro L. Effects of defibrotide on leukocytosis in rabbits with diet-induced atherosclerosis. Life Sci. 1995, 57:579-589.
117. Pfeifer C.A., Bottoms G.D., Johnson M.A., Fessler J. Leukotriene C4 disposition and metabolism in the anesthetized and endotoxemic dog. Circ. Shock. 1991, 33:68-83.
118. Pierangeli S.S., Espinola R.G., Liu X., Harris E.N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ. Res. 2001, 88:245-250.
119. Porta R., Calvani A.B., Pescador R., Mantovani M., Prino G. Absorption through the peritoneum of the macromolecular profibrinolytic drug defibrotide in the rabbit. Semin. Thromb. Hemost. 1991, 17:404-406.
120. Porta R., Conz A., Conto A., Pescador R., Mantovani M., Ferro L. Comparable beneficial effects of defibrotide and nifedipine in calcium induced atherosclerosis. Life Sci. 1994, 54:799-812.
121. Radice S., Rossoni G., Oriani G., Michael M., Chiesara E., Berti F. Hyperbaric oxygen worsens myocardial low flow ischemia-reperfusion injury in isolated rat heart. Eur. J. Pharmacol. 1997, 320:43-49.
122. Rand J.H. Molecular pathogenesis of the antiphospholipid syndrome. Circ. Res. 2002, 90:29-37.
123. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
124. Richardson P.G., Murakami C., Jin Z., Warren D., Momtaz P., Hoppensteadt D., Elias A.D., Antin J.H., Soiffer R., Spitzer T., Avigan D., Bearman S.I., Martin P.L., Kurtzberg J., Vredenburgh J., Chen A.R., Arai S., Vogelsang G., McDonald G.B., Guinan E.C. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002, 100:4337-4343.
125. Richardson P.G., Soiffer R.J., Antin J.H., Uno H., Jin Z., Kurtzberg J., Martin P.L., Steinbach G., Murray K.F., Vogelsang G.B., Chen A.R., Krishnan A., Kernan N.A., Avigan D.E., Spitzer T.R., Shulman H.M., Di Salvo D.N., Revta C., Warren D., Momtaz P., Bradwin G., Wei L.J., Iacobelli M., McDonald G.B., Guinan E.C. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol. Blood Marrow Transplant. 2010, 16:1005-1017.
126. Richardson P.G., Corbacioglu S., Ho V.T., Kernan N.A., Lehmann L., Maguire C., Maglio M., Hoyle M., Sardella M., Giralt S., Holler E., Carreras E., Niederwieser D., Soiffer R. Drug safety evaluation of defibrotide. Expert Opin. Drug Saf. 2013, 12:123-136.
127. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
128. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 1999, 138:S419-420.
129. Rossoni G., Sala A., Buccellati C., Maclouf J., Folco G.C., Berti F. Vasoconstriction to polymorphonuclear leukocytes in the isolated, perfused rabbit heart: inhibition by prostacyclin mimetics. J. Cardiovasc. Pharmacol. 1996, 27:680-685.
130. Rossoni G., Berti F., Trento F., Cattaneo F., Porta R., Pescador R., Ferro L. Chronic oral defibrotide counteracts hypercholesterolemia noxious effects on cardiovascular function in the rabbit. Thromb. Res. 1999, 94:327-338.
131. Rossoni G., Pompilio G., Biglioli P., Alamanni F., Tartara P., Rona P., Porqueddu M., Berti F. Protectant activity of defibrotide in cardioplegia followed by ischemia/reperfusion injury in the isolated rat heart. J. Card. Surg. 1999, 14:334-341.
132. Rossoni G., Berti F., Trento F., Cattaneo F., Porta R., Pescador R., Ferro L. Defibrotide normalizes cardiovascular function hampered by established atherosclerosis in the rabbit. Thromb. Res. 2000, 97:29-38.
133. Rossoni G., Manfredi B., De Gennaro Colonna V., Brini A.T., Polvani G., Clement M.G., Berti F. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol. Res. 2006, 53:359-366.
134. Sattar N., McInnes I.B. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr. Opin. Rheumatol. 2005, 17:286-292.
135. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
136. Scalia R., Kochilas L., Campbell B., Lefer A.M. Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin. Methods Find. Exp. Clin. Pharmacol. 1996, 18:669-676.
137. Scalia R., Pearlman S., Campbell B., Lefer A.M. Time course of endothelial dysfunction and neutrophil adherence and infiltration during murine traumatic shock. Shock 1996, 6:177-182.
138. Schroder H. Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity. J. Pharm. Pharmacol. 1995, 47:250-252.
139. Schror K., Ackermann G., Hohlfeld T., Lobel P., Ney P., Schroder H., Strobach H. Endothelial protection by defibrotide - a new strategy for treatment of myocardial infarction?. Z. Kardiol. 1989, 78(Suppl. 6):35-41.
140. Shah M.S., Jeevangi N.K., Joshi A., Khattry N. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide. J. Cancer Res. Ther. 2009, 5:312-314.
141. Shayevitz J.R., Miller C., Johnson K.J., Rodriguez J.L. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shock 1995, 4:389-396.
142. Shin Y.K., Campbell B., Lefer A.M. Novel beneficial effects of defibrotide, an endothelium protecting agent, following ischemia and reperfusion in the isolated perfused rat heart. Methods Find. Exp. Clin. Pharmacol. 1998, 20:463-471.
143. Shulman H.M., Fisher L.B., Schoch H.G., Henne K.W., McDonald G.B. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994, 19:1171-1181.
144. Smith J.A. Neutrophils, host defense, and inflammation: a double-edged sword. J. Leukoc. Biol. 1994, 56:672-686.
145. Stavrou E., Lazarus H.M. Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr. J. Hematol.Infect. Dis. 2010, 2:e2010033.
146. Subramaniam M., Frenette P.S., Saffaripour S., Johnson R.C., Hynes R.O., Wagner D.D. Defects in hemostasis in P-selectin-deficient mice. Blood 1996, 87:1238-1242.
147. Sucak G.T., Aki Z.S., Yagci M., Yegin Z.A., Ozkurt Z.N., Haznedar R. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant. Proc. 2007, 39:1558-1563.
148. Szotowski B., Antoniak S., Poller W., Schultheiss H.P., Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ. Res. 2005, 96:1233-1239.
149. Takatsuka H., Takemoto Y., Yamada S., Wada H., Tamura S., Fujimori Y., Okamoto T., Suehiro A., Kanamaru A., Kakishita E. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant. 2000, 26:419-426.
150. Tettamanti R., Bianchi G., Vitte P.A., Kato G., Porta R., Thiemermann C., Pescador R., Mantovani M. A novel insight into the mechanism of the antithrombotic action of defibrotide. Life Sci. 1992, 51:1545-1555.
151. Thiemermann C., Lobel P., Schror K. Usefulness of defibrotide in protecting ischemic myocardium from early reperfusion damage. Am. J. Cardiol. 1985, 56:978-982.
152. Thiemermann C., Thomas G.R., Vane J.R. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. Br. J. Pharmacol. 1989, 97:401-408.
153. Tsao P.S., Aoki N., Lefer D.J., Johnson G., Lefer A.M. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990, 82:1402-1412.
154. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011, 365:2110-2121.
155. Valdivielso P., Gomez-Doblas J.J., Macias M., Haro-Liger M., Fernandez-Nebro A., Sanchez-Chaparro M.A., Gonzalez-Santos P. Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis. Clin. Exp. Rheumatol. 2008, 26:827-833.
156. van Griensven M., Probst C., Muller K., Hoevel P., Pape H.C. Leukocyte-endothelial interactions via ICAM-1 are detrimental in polymicrobial sepsis. Shock 2006, 25:254-259.
157. Violi F., Marubini E., Coccheri S., Nenci G.G. Improvement of walking distance by defibrotide in patients with intermittent claudication - results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study. Thromb. Haemost. 2000, 83:672-677.
158. Viswambharan H., Ming X.F., Zhu S., Hubsch A., Lerch P., Vergeres G., Rusconi S., Yang Z. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ. Res. 2004, 94:918-925.
159. Wakefield T.W., Strieter R.M., Wilke C.A., Kadell A.M., Wrobleski S.K., Burdick M.D., Schmidt R., Kunkel S.L., Greenfield L.J. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:258-268.
160. Wakefield T.W., Strieter R.M., Schaub R., Myers D.D., Prince M.R., Wrobleski S.K., Londy F.J., Kadell A.M., Brown S.L., Henke P.K., Greenfield L.J. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J. Vasc. Surg. 2000, 31:309-324.
161. Weiss S.J. Tissue destruction by neutrophils. N. Engl. J. Med. 1989, 320:365-376.
162. Williams F.M., Parmar K., Hughes G.R., Hunt B.J. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb. Haemost. 2000, 84:742-746.
163. Wloch M.K., Pasquini S., Ertl H.C., Pisetsky D.S. The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. Hum. Gene Ther. 1998, 9:1439-1447.
164. Yakushijin K., Matsui T., Okamura A., Yamamoto K., Ito M., Chihara K. Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Kobe J. Med. Sci. 2005, 51:55-65.
165. Zampolli A., Basta G., Lazzerini G., Feelisch M., De Caterina R. Inhibition of endothelial cell activation by nitric oxide donors. J. Pharmacol. Exp. Ther. 2000, 295:818-823.
166. Zhou Q., Chu X., Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb. Haemost. 1994, 71:507-510.